IAIS 2021 3rd Annual Indiana Allergy Meeting

October 2, 2021

This meeting will provide learners with a range of treatments for severe atopic dermatitis, AERD, billing/coding updates and offering OIT in the medical office.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Indiana Allergy and Immunology Society. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participants should be able to:

  • Discuss a range of treatments available for severe atopic dermatitis and know which treatments may be best for each patient
  • Diagnose and treat AERD based on current guidelines
  • Optimise billing and coding practices, including telehealth
  • Discuss OIT options with food allergy patients
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Attendance
Course opens: 
Course expires: 
Event starts: 
10/02/2021 - 8:00am CDT
Event ends: 
10/02/2021 - 3:00pm CDT

 All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

David E Cohen, MD, MPH
Consultant and Honorarium:  Ferndale Laboratories, AsanaMedimetriks [past],Leo, UCB, Novartis, Dermavant, SFJ
FIDE. (FIDE receives industry sponsorship from AbbVie, Almirall, Amgen, Arcutis, Bausch and Lomb, Bristol-Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Regeneron, Sun Pharma, UCB, Valeant)

Brian Vickery, MD
Research Grant:  NIH-NIAID, Food Allergy Research and Education
Other research support:  Aimmune therapeutics, DBV technologies, Genentech, Regeneron, 
Consultant/advisory board:  Aimmune therapeutics, Aravax, AllerGenis, DBC, Food Allergy Research and Education, Reacta Biosciences

Maeve O’Connor, MD
Speaker: GlaskoSmithKline, Takeda, Teva, Astra Zeneca, Sanofi, Pharming, Circassia/Aerocine, Viropharma/Baxalta/Shire,  Regeneron, Optinose, GSK, Aimmune, Sanofi
Advisory Board: Strategic Pharmaceutical Strategic Allergy Advisors, Aimmune, Hycor, Precision, Pharming, Teva, ALK, Circassia, Spirometrix, Viropharma/Baxalta/Shire, Thermo Fisher Scientific

The following have no relevant financial relationships to disclose:
David Khan, MD
Joshua Milner, MD
Anne Maitland, MD, PHD

Available Credit

  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Attendance
Please login or create an account to take this course.